Immunotherapy for kidney cancer: status quo and the future
Sign Up to like & getrecommendations! Published in 2018 at "Current Opinion in Urology"
DOI: 10.1097/mou.0000000000000466
Abstract: Purpose of review The treatment landscape in advanced and metastatic renal cell carcinoma (RCC) is moving from the inhibition of tyrosine kinases (TKI) and the mammalian target of rapamycin (mTOR) inhibitors to specific immunooncology agents… read more here.
Keywords: immunotherapy kidney; phase; cancer status; immunooncology agents ... See more keywords